Evaluation and correlation of the physicochemical properties of carvedilol.

Pharm Dev Technol

b Mestrado Profissional em Gestão, Pesquisa e Desenvolvimento na Indústria Farmacêutica - Farmanguinhos, Fundação Oswaldo Cruz , Rio de Janeiro , Brazil.

Published: November 2016

Carvedilol is an antihypertensive drug with non-selective blockade (moderate selectivity for β1 and β2 adrenoceptors) and vasodilating properties due to α receptor blockade. Its molecule has one chiral centre; therefore, the drug has two enantiomers. Furthermore, it presents different polymorphs depending on the synthesis route and crystallization procedure. Carvedilol is a weak base that is substantially insoluble in water, acidic solutions, and gastric and intestinal fluids; it is classified as a Class II drug in the Biopharmaceutical Classification System. The solubility of carvedilol varies according to the solvent pH. This study aimed to evaluate and correlate the physicochemical and processability properties of carvedilol. Samples of the active ingredient from three different manufacturers were characterized according to their flowability, particle size and apparent density and using microscopy, differential scanning calorimetry (DSC), thermogravimetric analysis, X-ray diffraction, Fourier transform infrared spectroscopy, intrinsic dissolution and powder dissolution tests. It was determined that the tested samples presented the same polymorphic form, did not present good flowability, and presented different particle size distributions. The tests to evaluate flowability and compressibility were shown to be discriminative, and slight differences among the samples were noted.

Download full-text PDF

Source
http://dx.doi.org/10.3109/10837450.2015.1073740DOI Listing

Publication Analysis

Top Keywords

properties carvedilol
8
particle size
8
carvedilol
5
evaluation correlation
4
correlation physicochemical
4
physicochemical properties
4
carvedilol carvedilol
4
carvedilol antihypertensive
4
antihypertensive drug
4
drug non-selective
4

Similar Publications

The growing burden of metabolic disorders manifested by hypertension, type 2 diabetes mellitus, hyperlipidemia, obesity and non-alcoholic fatty liver disease presents a significant global health challenge by contributing to cardiovascular diseases and high mortality rates. Β-blockers are among the most widely used drugs in the treatment of hypertension and acute cardiovascular events. In addition to blocking the receptor sites for catecholamines, third-generation β-blockers with associated vasodilating properties, such as carvedilol and nebivolol, provide a broad spectrum of metabolic effects, including anti-inflammatory and antioxidant properties and a favorable impact on glucose and lipid metabolism.

View Article and Find Full Text PDF

High tissue density of the mammary gland is considered a pro-tumorigenic factor, hence suppressing the stimuli that induce matrix buildup carries the potential for cancer interception. We found that in non-malignant mammary epithelial cells the combination of the chemopreventive agents bexarotene (Bex) and carvedilol (Carv) suppresses the zymogen granule protein 16B (ZG16B, PAUF) through an interaction of ARID1A with a proximal enhancer. Bex + Carv also reduced ZG16B levels in vivo in normal breast tissue and MDA-MB231 tumor xenografts.

View Article and Find Full Text PDF

Cardiovascular diseases remain a leading cause of morbidity and mortality worldwide, requiring innovative therapeutic strategies. This project explores a nano-pharmaceutical approach to enhance the efficacy of cardiovascular drugs, focusing on carvedilol and curcumin. These agents, known for their potential cardiovascular benefits, are encapsulated within Soluplus® micelles to form a novel drug delivery system.

View Article and Find Full Text PDF

Carvedilol inhibits neuronal hyperexcitability caused by epilepsy-associated KCNT1 mutations.

Br J Pharmacol

January 2025

State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, China.

Article Synopsis
  • KCNT1 mutations, like M267T, are linked to epilepsy, and traditional medications are often ineffective for affected patients.
  • This study investigated the mutation's effects on neuronal activity and tested carvedilol, an FDA-approved drug, for its ability to reverse the mutation's harmful effects.
  • Results showed carvedilol improved channel function and reduced seizure activity in mice, suggesting it may be a promising treatment option for epilepsy related to KCNT1 mutations.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!